
Payer decision-makers discuss defining value among agents for unintended pregnancy, uterine fibroids, and endometriosis.
Payer decision-makers discuss defining value among agents for unintended pregnancy, uterine fibroids, and endometriosis.
A panel of experts discuss treatment selection among contraceptive agents and evolving treatment strategies for uterine fibroids and endometriosis.
Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.
Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.
Kevin Stephens, Sr. MD, JD examines key drivers of healthcare utilization for women of childbearing years.
Steven McCarus, MD FACOG highlights the shift away from surgical treatment toward medical therapy in UF and endometriosis.
Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.
Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.
Published: April 22nd 2022 | Updated:
Published: April 22nd 2022 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.